187 related articles for article (PubMed ID: 30030117)
21. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
22. Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma.
Lu J; Chen XM; Huang HR; Zhao FP; Wang F; Liu X; Li XP
Head Neck; 2018 Jun; 40(6):1245-1253. PubMed ID: 29493822
[TBL] [Abstract][Full Text] [Related]
23. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M
Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069
[TBL] [Abstract][Full Text] [Related]
24. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
25. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.
Swisher SK; Wu Y; Castaneda CA; Lyons GR; Yang F; Tapia C; Wang X; Casavilca SA; Bassett R; Castillo M; Sahin A; Mittendorf EA
Ann Surg Oncol; 2016 Jul; 23(7):2242-8. PubMed ID: 26965699
[TBL] [Abstract][Full Text] [Related]
26. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma.
Tang Y; He Y; Shi L; Yang L; Wang J; Lian Y; Fan C; Zhang P; Guo C; Zhang S; Gong Z; Li X; Xiong F; Li X; Li Y; Li G; Xiong W; Zeng Z
Oncotarget; 2017 Jun; 8(24):39001-39011. PubMed ID: 28380458
[TBL] [Abstract][Full Text] [Related]
27. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
[TBL] [Abstract][Full Text] [Related]
28. The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer.
Zhang XL; Jiang C; Zhang ZX; Liu F; Zhang F; Cheng YF
Oncol Res Treat; 2014; 37(9):480-4. PubMed ID: 25231688
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage.
Pujani M; Jain H; Chauhan V; Agarwal C; Singh K; Singh M
Breast Dis; 2020; 39(2):61-69. PubMed ID: 32310155
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
[TBL] [Abstract][Full Text] [Related]
31. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma.
Hoesli R; Birkeland AC; Rosko AJ; Issa M; Chow KL; Michmerhuizen NL; Mann JE; Chinn SB; Shuman AG; Prince ME; Wolf GT; Bradford CR; McHugh JB; Brenner JC; Spector ME
Oral Oncol; 2018 Feb; 77():83-89. PubMed ID: 29362129
[TBL] [Abstract][Full Text] [Related]
32. Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients.
Fuchs TL; Sioson L; Sheen A; Jafari-Nejad K; Renaud CJ; Andrici J; Ahadi M; Chou A; Gill AJ
Am J Surg Pathol; 2020 Apr; 44(4):536-544. PubMed ID: 31743129
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of an individualized angiogenesis and tumor-infiltrating lymphocytes prognostic signature in nasopharyngeal carcinoma.
Zhang R; Liao X; Zhang B; Huang X; Qin G; Kong X; Xie Y; Mo Y; Dai J; Gan C; Luo Z; Lu J; Jiang W
Pathol Res Pract; 2024 Jan; 253():154936. PubMed ID: 38006840
[TBL] [Abstract][Full Text] [Related]
35. The ICOSL Expression Predicts Better Prognosis for Nasopharyngeal Carcinoma via Enhancing Oncoimmunity.
Zhang G; Xu Y; Zhang S; Zhou H
Biomed Res Int; 2020; 2020():9756732. PubMed ID: 31998801
[TBL] [Abstract][Full Text] [Related]
36. The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients.
Jiang R; Zou X; Hu W; Fan YY; Yan Y; Zhang MX; You R; Sun R; Luo DH; Chen QY; Huang PY; Hua YJ; Guo L; Chen MY
Tumour Biol; 2015 Sep; 36(10):7775-87. PubMed ID: 25944165
[TBL] [Abstract][Full Text] [Related]
37. Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups.
Lang-Schwarz C; Melcher B; Haumaier F; Lang-Schwarz K; Rupprecht T; Vieth M; Sterlacci W
Hum Pathol; 2018 Sep; 79():160-167. PubMed ID: 29787819
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
[TBL] [Abstract][Full Text] [Related]
39. Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma.
Zhao J; Guo C; Xiong F; Yu J; Ge J; Wang H; Liao Q; Zhou Y; Gong Q; Xiang B; Zhou M; Li X; Li G; Xiong W; Fang J; Zeng Z
Cancer Lett; 2020 May; 477():131-143. PubMed ID: 32061950
[TBL] [Abstract][Full Text] [Related]
40. The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment.
Chen TC; Chen CH; Wang CP; Lin PH; Yang TL; Lou PJ; Ko JY; Wu CT; Chang YL
Sci Rep; 2017 Sep; 7(1):10349. PubMed ID: 28871094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
